

one of claims **1-13**, the conjugate according to claim **14**, or the pharmaceutical composition of claim **15** in an effective amount to said cell.

17. A method for treating or preventing a disease comprising administering a therapeutically or prophylactically effective amount of an oligonucleotide of any one of claims **1-13** or the conjugate according to claim **14** or the pharmaceutical composition of claim **15** to a subject suffering from or susceptible to the disease.

18. The method of claim **17**, wherein the disease is a neurological disorder, such as a neurological disorder selected from the group consisting of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), tauopathy (such as primary tauopathy), frontotemporal dementia with parkinsonism (FTDP-17), frontotemporal lobar dementia (FTLD-TDP), Huntington's disease, Creutzfeld-Jacob disease, and spinomuscular atrophy, motor neuron disease, Tauopathy, Alzheimer's disease, and Weller distal myopathy.

19. The oligonucleotide of any one of claims **1-13** or the conjugate according to claim **14** or the pharmaceutical composition of claim **15** for use in medicine.

20. The oligonucleotide of any one of claims **1-13** or the conjugate according to claim **14** or the pharmaceutical composition of claim **15** for use in the treatment or prevention of a neurological disorder, such as a neurological disorder selected from the group consisting of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD),

tauopathy (such as primary tauopathy), frontotemporal dementia with parkinsonism (FTDP-17), frontotemporal lobar dementia (FTLD-TDP), Huntington's disease, Creutzfeld-Jacob disease, and spinomuscular atrophy, motor neuron disease, Tauopathy, Alzheimer's disease, and Weller distal myopathy.

21. Use of the oligonucleotide of claims **1-13** or the conjugate according to claim **14** or the pharmaceutical composition of claim **15**, for the preparation of a medication for treatment or prevention of a neurological disorder, such as a neurological disorder selected from the group consisting of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), frontotemporal dementia with parkinsonism (FTDP-17), frontotemporal lobar dementia (FTLD-TDP), tauopathy (such as primary tauopathy), Huntington's disease, Creutzfeld-Jacob disease, and spinomuscular atrophy, motor neuron disease, Tauopathy, Alzheimer's disease, and Weller distal myopathy.

22. The Use of method according to any one of claims **17-21**, wherein the neurological disorder is Amyotrophic Lateral Sclerosis (ALS).

23. The Use of method according to any one of claims **17-21**, wherein the neurological disorder is a tauopathy, such as a primary tauopathy.

24. The Use of method according to any one of claims **17-21**, wherein the neurological disorder is frontotemporal lobar dementia (FTLD-TDP).

* * * * *